Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is ...

Two-year cumulative rate of invasive ipsilateral breast cancer was 5.9 and 4.2% for guideline-concordant care, active monitoring HealthDay News — For patients with ductal carcinoma in situ (DCIS), ...

SURGE Therapeutics (SURGE) is a provider of intraoperative immunotherapy services for cancer patients that offers an injectable biodegradable hydrogel and allows prolonged, localized free-up of most ...

AI-supported mammography screening significantly increases breast cancer detection rates while maintaining comparable recall ...

A new study, published in the New England Journal of Medicine, examines whether removing lymph nodes is always necessary in ...

Women with Stage 0 breast cancer who got biannual mammograms and delayed surgery for two years fared as well as those who got immediate surgery.

Inside Edition’ reporter Alison Hall says Olivia Munn deciding to share her cancer diagnosis helped save her life ...

"After something so terrible, it's so nice to be able to do something positive for the community." Gina Gray, who was ...

SALT LAKE CITY, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced an agreement with Hannah Storm, a nationally ...

In 2014, doctors diagnosed Laura Colletti, of Pittsbor, with ductal carcinoma in situ, or DCIS. “It’s scary, she said. “I initially felt some dread and I was nervous about it.” She was ...

Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.